Quantification of IgE antibodies simplifies the classification of allergic diseases in 4-year-old children. A report from the prospective birth cohort study – BAMSE

Authors

  • Magnus Wickman,

    1. Department of Occupational and Environmental Health, Stockholm County Council, Stockholm, Sweden
    2. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    3. Sachs's Children's Hospital, Institute of Södersjukhuset, Karolinska Institute, Stockholm, Sweden
    4. Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
    Search for more papers by this author
  • Staffan Ahlstedt,

    1. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    2. Pharmacia Diagnostics AB, Uppsala, Sweden
    3. Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
    Search for more papers by this author
  • Gunnar Lilja,

    1. Sachs's Children's Hospital, Institute of Södersjukhuset, Karolinska Institute, Stockholm, Sweden
    Search for more papers by this author
  • Marianne v Hage Hamsten

    1. Department of Medicine, Unit of Clinical Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden
    2. Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden
    Search for more papers by this author

Magnus Wickman, Department of Occupational and Environmental Health, Norrbacka, Level 3, Karolinska Hospital, SE-171 76 Stockholm, Sweden
Tel.: +468 5177 7912
Fax: +468 5177 7900
E-mail: magnus.wickman@smd.sll.se

Abstract

Allergic diseases are common among small children, but it is still unclear how immunoglobulin E (IgE) antibodies to ambient allergens are distributed in a population-based prospective material of children at 4 years of age. The study is based on 75% (n = 4089) of all eligible children from northern Stockholm, born between 1994 and 1996 in pre-defined geographical areas. Data on exposure and outcome were obtained by parental questionnaires when the child was 3 months and 4 years of age. Of the 92% who responded to the 4 years of age questionnaire, serum was obtained in 88% of these children for analysis of IgE antibodies performed with Pharmacia CAP systemTM (Phadiatop® and food mix fx5®). An antibody level ≥0.35 kUA/l was considered as positive. A positive Phadiatop® or fx5® was found in 24% of the 4 years old children. A rather poor correlation was found between the two tests (r = 0.39). Occurrence of IgE antibodies ≥3.5 kU/l for both Phadiatop® and fx5® in combination could predict any suspected allergic disease [asthma, rhinitis, atopic eczema dermatitis syndrome (AEDS) and allergic reaction to food] to 97.4%. However, the presence of ≥3.5 kUA/l of Phadiatop® or fx5® used as single tests only, was far less efficient to predict any allergic disease. The two mixes of airborne and food allergens were also associated, not only to the severity of the allergic disease in terms of number of organ involved, but also to the severity of recurrent wheeze, in particular in boys with a positive Phadiatop® who exhibited significantly limited peak flows compared to those with a negative test.

Already at the age of 4, one child in four is sensitized to an allergen as assessed by Phadiatop® or food mix (fx5®). The presence of IgE antibodies seems not only to predict allergic diseases in this age group, but also relates to severity of such diseases, in particular to asthma. Notable, there was a poor correlation between Phadiatop® and fx5® that needs to be considered when identifying allergic diseases in young children. The study demonstrates that quantification of IgE antibodies in blood may be beneficial, not only to diagnose allergic diseases in young children, but especially to serve as a marker of severity of asthma.

Ancillary